← All trials
NCT03762772
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 10, 2018
- Primary completion
- May 31, 2019
- Completion date
- Jun 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CONRADLead sponsor
- United States Agency for International DevelopmentCollaborator
- CONRADStudy director
- Eastern Virginia Medical SchoolCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.